The Pharma Data

FEBRUARY 21, 2022

Our leadership in cardiology, radiology and women’s health is recognized worldwide, and we are expanding our presence in oncology, working tirelessly to bring forward new approaches that can change the treatment paradigm for patients,” said Stefan Oelrich, Member of the Board of Management, Bayer AG and President of Bayer’s Pharmaceuticals Division.

Radiology 52

Radiology Cardiology Development Production 52

Scienmag

FEBRUARY 16, 2021

Food and Drug Administration (FDA)’s Center for Devices and Radiological Health (CDRH) will participate in this “collaborative community” A medical “collaboratory” is a forum in which multidisciplinary private and public sector members work together on medical […].

Radiology 48

Radiology Drugs Clinical Trials Clinical Trials 48

XTalks

JANUARY 19, 2024

Currently, several alpha particle emitters are being investigated in clinical trials. Advantages of Alpha Emitter Therapy Over the past two decades, the radiological and chemical properties of alpha emitting isotopes have regained prominence in medical physics. Guarnaschelli in the webinar. References The Green Journal.

DNA 66

DNA Radiology FDA Approval Development 66

XTalks

SEPTEMBER 11, 2024

In recent years, the landscape of women’s health clinical trials has begun to shift. Read on to learn more about the historical challenges, recent advancements, clinical considerations, and the future of women’s health clinical trials, as detailed by Medpace’s women’s health experts.

Clinical Trials 103

Clinical Trials Clinical Trials Trials Hormones 103

The Pharma Data

OCTOBER 14, 2020

Michael Felker, MD, MHS, FACC, FAHA, FHFSA is Professor of Medicine with tenure in the Division of Cardiology at Duke University School of Medicine. He is Director of Cardiovascular Research at the Duke Clinical Research Institute and Vice-Chief for Clinical Research in the Division of Cardiology.

Cardiology 40

Cardiology Clinical Trials Clinical Trials Medicine 40